Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Profit After Tax (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Profit After Tax for 16 consecutive years, with $900000.0 as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 136.2% to $900000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.3 million through Dec 2025, down 14.99% year-over-year, with the annual reading at -$10.9 million for FY2025, 23.24% down from the prior year.
  • Profit After Tax for Q4 2025 was $900000.0 at Anika Therapeutics, up from -$2.3 million in the prior quarter.
  • The five-year high for Profit After Tax was $16.2 million in Q4 2023, with the low at -$10.4 million in Q1 2023.
  • Average Profit After Tax over 5 years is -$815500.0, with a median of -$2.6 million recorded in 2023.
  • The sharpest move saw Profit After Tax surged 309.75% in 2022, then tumbled 4411.36% in 2025.
  • Over 5 years, Profit After Tax stood at -$5.8 million in 2021, then soared by 309.75% to $12.2 million in 2022, then skyrocketed by 33.55% to $16.2 million in 2023, then tumbled by 115.32% to -$2.5 million in 2024, then soared by 136.2% to $900000.0 in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at $900000.0, -$2.3 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.